tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
MannKind’s Clofazimine Inhalation Study Terminated: Implications for Investors
PremiumCompany AnnouncementsMannKind’s Clofazimine Inhalation Study Terminated: Implications for Investors
26d ago
MannKind says FDA accepts for review its sNDA of of FUROSCIX ReadyFlow
Premium
The Fly
MannKind says FDA accepts for review its sNDA of of FUROSCIX ReadyFlow
1M ago
MannKind initiated with a Buy at Truist
Premium
The Fly
MannKind initiated with a Buy at Truist
2M ago
MannKind’s Resilience and Growth Potential: A Buy Rating Amid Setbacks and Opportunities
PremiumRatingsMannKind’s Resilience and Growth Potential: A Buy Rating Amid Setbacks and Opportunities
2M ago
MannKind Halts Phase 3 Trial for MNKD-101
Premium
Company Announcements
MannKind Halts Phase 3 Trial for MNKD-101
2M ago
MannKind provides update on Phase 3 ICoN-1 trial of nebulized clofazimine
Premium
The Fly
MannKind provides update on Phase 3 ICoN-1 trial of nebulized clofazimine
2M ago
MannKind reports Q3 EPS 7c, consensus 3c
PremiumThe FlyMannKind reports Q3 EPS 7c, consensus 3c
2M ago
MNKD Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
MNKD Earnings this Week: How Will it Perform?
2M ago
Strong Revenue Growth and Strategic Developments Support MannKind’s Buy Rating
Premium
Ratings
Strong Revenue Growth and Strategic Developments Support MannKind’s Buy Rating
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100